Quantum Cyber Launches Second $100M Share-Sale Program in Four Months
Company Background
Quantum Cyber N.V. (Nasdaq: QUCY) entered 2026 as Mainz Biomed N.V., a Dutch molecular diagnostics company whose flagship product was a colorectal cancer screening test sold in European markets. That identity was abandoned quickly: in February 2026 investor David Lazar invested $6 million in convertible preferred shares, ultimately acquiring over 95% of the company's voting rights. The board wound down the colorectal cancer program, sold both the ColoAlert intellectual property and next-generation colorectal IP for a combined $1.25 million, shuttered the German subsidiary, renamed the company Quantum Cyber N.V., and changed the ticker to QUCY on March 12, 2026.
The company has since repositioned itself around autonomous defense drones, quantum antenna technology, and post-quantum cybersecurity. It acquired a roughly 50,000-square-foot manufacturing facility in Bridgeport, Connecticut in July 2026, stood up an 80-unit 3D printing drone production operation there by August 31, 2026, and entered IP licensing agreements with BP United Inc. and Project LightShift covering drone-integrated quantum antenna systems. Letters of intent with Ukrainian drone maker General Cherry and with U.S. Special Operations Command have been announced but no revenues from any of these new activities have been disclosed.
The financial backdrop has been complicated throughout the transition. Stockholders' equity stood at $641,600 as of December 31, 2025 — below the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1) — and the company's shares briefly fell below the $1.00 minimum bid price threshold, generating a second Nasdaq deficiency notice in March 2026. The prior independent auditor, Reliant CPA PC, included a going concern paragraph in its reports on both the 2024 and 2025 financial statements. Reliant was replaced by Haskell & White LLP in June 2026. The bid price deficiency was resolved by May 28, 2026, and the company believes the $6 million Lazar investment cured the equity deficiency.
What Was Disclosed
On October 9, 2026, Quantum Cyber entered into a sales agreement with Titan Partners Securities LLC establishing an at-the-market offering program under which the company may sell up to $100 million of its ordinary shares from time to time. The agent earns a commission of 3.0% of the gross sales price on each transaction. Shares are registered under a shelf registration statement on Form S-3 (File No. 333-296480) initially filed June 4, 2026 and declared effective June 15, 2026 — a new shelf distinct from the older F-3 shelf that underpinned prior Maxim transactions. The company is not obligated to sell any shares; the offering terminates when all shares are sold or the agreement is terminated.